1.0CureVachttps://www.curevac.com/en/CureVac Chief Technology Officer to Pursue New Career outside Biotech Industryrich600338<blockquote class="wp-embedded-content" data-secret="CKTyQzopKZ"><a href="https://www.curevac.com/en/curevac-chief-technology-officer-to-pursue-new-career-outside-biotech-industry/">CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://www.curevac.com/en/curevac-chief-technology-officer-to-pursue-new-career-outside-biotech-industry/embed/#?secret=CKTyQzopKZ" width="600" height="338" title="“CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry” — CureVac" data-secret="CKTyQzopKZ" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript">
/* <![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
/* ]]> */
</script>
CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that the company’s Chief Technology Officer, Dr. Mariola Fotin-Mleczek, will resign from CureVac effective January 31, 2022. Mariola exits her role at CureVac after nearly 16 years of scientific leadership at the company, and 33 years in Germany, with plans to pursue a family business outside the biotech industry in her home country of Poland.https://www.curevac.com/wp-content/uploads/2021/02/CureVac-Logo-Social.png1200630